This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. BMRA, CDIO, VRAX, AWH, TNFA, MYMD, NAVB, IDXX, LNTH, and QDELShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include Biomerica (BMRA), Cardio Diagnostics (CDIO), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), Lantheus (LNTH), and QuidelOrtho (QDEL). These companies are all part of the "medical" sector. Akers Biosciences vs. Its Competitors Biomerica Cardio Diagnostics Virax Biolabs Group Aspira Women's Health TNF Pharmaceuticals MyMD Pharmaceuticals Navidea Biopharmaceuticals IDEXX Laboratories Lantheus QuidelOrtho Akers Biosciences (NASDAQ:AKER) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Do insiders and institutionals believe in AKER or BMRA? 5.5% of Akers Biosciences shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 0.3% of Akers Biosciences shares are owned by insiders. Comparatively, 15.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, AKER or BMRA? Akers Biosciences has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Is AKER or BMRA more profitable? Akers Biosciences has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat Akers Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Akers BiosciencesN/A -87.42% -73.31% Biomerica -85.42%-85.90%-61.06% Does the media favor AKER or BMRA? In the previous week, Biomerica had 5 more articles in the media than Akers Biosciences. MarketBeat recorded 5 mentions for Biomerica and 0 mentions for Akers Biosciences. Biomerica's average media sentiment score of 0.47 beat Akers Biosciences' score of 0.00 indicating that Biomerica is being referred to more favorably in the news media. Company Overall Sentiment Akers Biosciences Neutral Biomerica Neutral Which has higher earnings and valuation, AKER or BMRA? Akers Biosciences has higher earnings, but lower revenue than Biomerica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkers Biosciences$1.58M1.37-$3.89MN/AN/ABiomerica$5.41M1.48-$5.98M-$2.32-1.36 SummaryBiomerica beats Akers Biosciences on 9 of the 11 factors compared between the two stocks. Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17M$18.11M$5.48B$8.87BDividend YieldN/AN/A5.37%4.16%P/E RatioN/AN/A25.9019.58Price / Sales1.3716.96386.89105.06Price / CashN/AN/A36.4056.81Price / Book0.020.027.875.44Net Income-$3.89M-$15.61M$3.15B$248.88M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.13+3.6%N/A-93.1%$2.17M$1.58M0.004High Trading VolumeBMRABiomerica0.4171 of 5 stars$3.33-0.4%N/A-12.4%$8.47M$5.68M-9.7860News CoverageCDIOCardio Diagnostics3.2133 of 5 stars$3.72-5.8%$60.00+1,512.9%-78.0%$6.47M$19.90K0.001VRAXVirax Biolabs Group3.6061 of 5 stars$0.82-5.9%$3.00+266.3%-33.9%$2.65M$84.87K0.005Positive NewsAWHAspira Women's Health0.8401 of 5 stars$0.08-12.5%$5.50+6,607.3%-93.7%$2.44M$9.18M-0.07110High Trading VolumeTNFATNF PharmaceuticalsN/A$0.15+2.6%N/AN/A$2.13MN/A-0.026News CoveragePositive NewsMYMDMyMD PharmaceuticalsN/A$0.15+6.6%N/A-93.3%$346KN/A0.006High Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A+0.0%$70K$8.13K0.0010IDXXIDEXX Laboratories3.6831 of 5 stars$520.59-1.5%$546.00+4.9%+7.6%$41.87B$3.93B48.7910,800Positive NewsLNTHLantheus4.2778 of 5 stars$77.92+0.1%$132.67+70.3%+0.2%$5.39B$1.54B12.97700QDELQuidelOrtho4.2996 of 5 stars$28.03-4.1%$44.33+58.2%-13.9%$1.90B$2.76B-0.937,000 Related Companies and Tools Related Companies Biomerica Alternatives Cardio Diagnostics Alternatives Virax Biolabs Group Alternatives Aspira Women's Health Alternatives TNF Pharmaceuticals Alternatives MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives IDEXX Laboratories Alternatives Lantheus Alternatives QuidelOrtho Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Knows Exactly What He’s Doing…With Trump in office, new money is flowing in and out of the market like never before... And some folks usi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKER Stock Free AKER Stock Alerts